Development and mechanism of fluoroquinolone resistance in Legionella pneumophila

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 2, 2003, Pages 275-280

  Jonas, Daniel ^a   Engels, Inge ^a   Hartung, Doris ^a   Beyersmann, Jan ^a   Frank, Uwe ^a   Daschner, Franz D ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Fluoroquinolone resistance; gyrA; Legionella pneumophila

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; ISOLEUCINE; LEVOFLOXACIN; LYSINE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THREONINE; TROVAFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; DRUG TARGETING; GENE SEQUENCE; IN VITRO STUDY; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW;

AMINO ACID SUBSTITUTION; ANTI-INFECTIVE AGENTS; CODON; CULTURE MEDIA; DNA GYRASE; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; LEGIONELLA PNEUMOPHILA; MICROBIAL SENSITIVITY TESTS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0037323918     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg054     Document Type: Review

References (31)

1. Moffie, B. G. & Mouton, R. P. (1988). Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics. Journal of Antimicrobial Chemotherapy 22, 457-62.
2. Zhao, X., Xu, C., Domagala, J. & Drlica, K. (1997). DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proceedings of the National Academy of Sciences, USA 94, 13991-6.
3. Carmeli, Y., Troillet, N., Eliopoulos, G. M. & Samore, M. H. (1999). Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrobial Agents and Chemotherapy 43, 1379-82.
4. Unertl, K. E., Lenhart, F. P., Forst, H., Vogler, G., Wilm, V., Ehret, W. et al. (1989). Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin. American Journal of Medicine 87, 128S-31S.
5. Kurz, R. W., Graninger, W., Egger, T. P., Pichler, H. & Tragl, K. H. (1988). Failure of treatment of legionella pneumonia with ciprofloxacin. Journal of Antimicrobial Chemotherapy 22, 389-91.
6. Jonas, D., Rosenbaum, A., Weyrich, S. & Bhakdi, S. (1995). Enzyme-linked immunoassay for detection of PCR-amplified DNA of legionellae in bronchoalveolar fluid. Journal of Clinical Microbiology 33, 1247-52.
7. Pruckler, J. M., Mermel, L. A., Benson, R. F., Giorgio, C., Cassiday, P. K., Breiman, R. F. et al. (1995). Comparison of Legionella pneumophila isolates by arbitrarily primed PCR and pulsed-field gel electrophoresis: analysis from seven epidemic investigations. Journal of Clinical Microbiology 33, 2872-5.
8. Edelstein, P. H. & Edelstein, M. A. (1989). WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages. Antimicrobial Agents and Chemotherapy 33, 2132-6.
9. Edelstein, P. H. & Edelstein, M. A. (1992). In vitro activity of Ro 23-9424 against clinical isolates of Legionella species. Antimicrobial Agents and Chemotherapy 36, 2559-61.
10. Jonas, D., Meyer, H. G., Matthes, P., Hartung, D., Jahn, B., Daschner, F. D. et al. (2000). Comparative evaluation of three different genotyping methods for investigation of nosocomial outbreaks of Legionnaires' disease in hospitals. Journal of Clinical Microbiology 38, 2284-91.
11. Feddersen, A., Meyer, H. G., Matthes, P., Bhakdi, S. & Husmann, M. (2000). GyrA sequence-based typing of legionella. Medical Microbiology and Immunology 189, 7-11.
12. Wilcoxon, F. & Wilcox, R. A. (1964). Some Rapid Approximate Statistical Procedures. Lederle Laboratories, New York, NY, USA.
13. Columbia Genome Center Legionella Project. (1999). Legionella Genome Project. [Online.] http://genome3.c.p.m.c.columbia.edu/~legion/ (14 October 2002, date last accessed).
14. Edelstein, P. H. (1995). Antimicrobial chemotherapy for legionnaires' disease: a review. Clinical Infectious Diseases 21, Suppl. 3, 5265-76.
15. Fraser, D. W., Tsai, T. R., Orenstein, W., Parkin, W. E., Beecham, H. J., Sharrar, R. G. et al. (1977). Legionnaires' disease: description of an epidemic of pneumonia. New England Journal of Medicine 297, 1189-97.
16. Davis, G. S., Winn, W. C., Jr. & Beaty, H. N. (1981). Legionnaires Disease. Infections caused by Legionella pneumophila and Legionella-like organisms. Clinics in Chest Medicine. 2, 145-66.
17. Dowling, J. N., McDevitt, D. A. & Pasculle, A. W. (1985). Isolation and preliminary characterization of erythromycin-resistant variants of Legionella micdadei and Legionella pneumophila. Antimicrobial Agents and Chemotherapy 27, 272-4.
18. Bingen, E., Lambert-Zechovsky, N., Mariani-Kurkdjian, P., Doit, C., Aujard, Y., Fournerie, F. et al. (1990). Bacterial counts in cerebrospinal fluid of children with meningitis. European Journal of Clinical Microbiology and Infectious Diseases 9, 278-81.
19. Mitchison, D. A. (1984). Drug resistance in mycobacteria. British Medical Bulletin 40, 84-90.
20. Feldman, W. E. (1976). Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. Journal of Pediatrics 88, 549-52.
21. Edelstein, P. H. (1991). Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease. Antimicrobial Agents and Chemotherapy 35, 5-9.
22. Rudin, J. E., Evans, T. L. & Wing, E. J. (1984). Failure of erythromycin in treatment of Legionella micdadei pneumonia. American Journal of Medicine 76, 318-20.
23. Salord, J. M., Matsiota-Bernard, P., Staikowsky, F., Kirstetter, M., Frottier, J. & Nauciel, C. (1993). Unsuccessful treatment of Legionella pneumophila infection with a fluoroquinolone. Clinical Infectious Diseases 17, 518-9.
24. Peterson, L. R. (2001). Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clinical Infectious Diseases 33, Suppl. 3, S180-6.
25. Schmitz, F. J., Boos, M., Mayer, S., Hafner, D., Jagusch, H., Verhoef, J. et al. (2001). Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 45, 2666-7.
26. Linde, H., Morgenroth, K., Barabas, S. & Lehn, N. (2002). The amino acid substitution Asp87Tyr in GyrA of Legionella pneumophila Sg1 is associated with elevated MICs to nalidixic acid but not to ciprofloxacin or moxifloxacin in vitro. International Journal of Medical Microbiology 292, Suppl. 34, 137-8.
27. Barker, J., Scaife, H. & Brown, M. R. (1995). Intraphagocytic growth induces an antibiotic-resistant phenotype of Legionella pneumophila. Antimicrobial Agents and Chemotherapy 39, 2684-8.
28. Garduno, R. A., Garduno, E., Hiltz, M. & Hoffman, P. S. (2002). Intracellular growth of Legionella pneumophila gives rise to a differentiated form dissimilar to stationary-phase forms. Infection and Immunity 70, 6273-83.
29. Hooper, D. C. (1999). Mechanisms of fluoroquinolone resistance. Drug Resistance Updates 2, 38-55.
30. Piddock, L. J. (1999). Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58, Suppl. 2, 11-8.
31. Barnard, F. M. & Maxwell, A. (2001). Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrobial Agents and Chemotherapy 45, 1994-2000.